Nektar Therapeutics (NKTR) Stock Forecast
NKTR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.40 / 5 from 15 analysts
- Price target
- $133.08 average of analyst targets
- Upside to target
- +271.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-2.16
- 52-week range
- $35.12 – $100.35
NKTR analyst ratings
15 analystsNumber of analysts at each rating.
NKTR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NKTR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.07 | −$3.07 | −$1.71 | −$1.87 | −10.7% | 15 |
| Current fiscal year (2026) | −$8.08 | −$9.63 | −$6.89 | −$9.73 | +16.9% | 15 |
| Next fiscal year (2027) | −$10.50 | −$20.03 | −$4.10 | −$8.08 | −29.9% | 15 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NKTR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $10.4M | $9.5M | $12.0M | −11.8% | 15 |
| Current fiscal year (2026) | $41.8M | $40.0M | $45.0M | −24.3% | 15 |
| Next fiscal year (2027) | $53.4M | $8.1M | $290.8M | +27.7% | 15 |
NKTR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NKTR revenue: reported and forecast
NKTR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.15 | −$2.14 | −$2.13 | −$2.10 | −$2.07 | −3.8% | 2 up · 0 down |
| Current fiscal year (2026) | −$8.97 | −$9.01 | −$8.18 | −$8.09 | −$8.08 | −9.9% | 2 up · 0 down |
| Next fiscal year (2027) | −$11.02 | −$10.85 | −$10.53 | −$10.25 | −$10.50 | −4.7% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NKTR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NKTR beat in 7 of 12.
What analysts expect from NKTR
15 analysts cover Nektar Therapeutics; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $133.08, 271.9% above the latest close of $35.78. Analysts expect earnings of −$8.08 per share for 2026, +16.9% from a year earlier. For 2027 the average estimate is −$10.50 per share on revenue of $53.4 million. Nektar Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: NKTR income statement, NKTR key metrics, NKTR chart. See the NKTR stock overview for the latest quote and news.
NKTR forecast FAQ
What is Nektar Therapeutics's price target?
The average analyst price target for Nektar Therapeutics is $133.08, 271.9% above the latest close of $35.78.
Is Nektar Therapeutics a buy, hold or sell?
Of 15 analysts covering Nektar Therapeutics, 10 rate it a strong buy, 1 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nektar Therapeutics's EPS forecast?
Analysts forecast −$8.08 per share for 2026 (range −$9.63 to −$6.89); for 2027 the estimate is −$10.50.
What is Nektar Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $41.8 million, growth of −24.3%; for 2027 it is $53.4 million.
When does Nektar Therapeutics report earnings?
Nektar Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-2.16.
Does Nektar Therapeutics usually beat earnings estimates?
Nektar Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.